|
KR101531400B1
(ko)
|
2003-06-27 |
2015-06-26 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
|
|
WO2008027986A2
(en)
|
2006-09-01 |
2008-03-06 |
Therapeutic Human Polyclonals, Inc. |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
|
HRP20140049T1
(hr)
|
2007-01-05 |
2014-02-28 |
University Of Zürich |
Anti beta-amiloid antitijela i njihova upotreba
|
|
WO2010069603A1
(en)
|
2008-12-19 |
2010-06-24 |
Neurimmune Therapeutics Ag |
Human anti-alpha-synuclein autoantibodies
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
CN103237901B
(zh)
|
2010-03-01 |
2016-08-03 |
卡里斯生命科学瑞士控股有限责任公司 |
用于治疗诊断的生物标志物
|
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
|
TWI636993B
(zh)
*
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Ｄｋｋ１抗體及使用方法
|
|
JP2014508523A
(ja)
*
|
2011-02-23 |
2014-04-10 |
ヘルス リサーチ インコーポレイテッド |
抗エンドグリン抗体及び新規ヒト／マウスキメラエンドグリンを発現するノックインマウス
|
|
JP2014509588A
(ja)
*
|
2011-03-01 |
2014-04-21 |
アムジエン・インコーポレーテツド |
二特異性結合剤
|
|
US9255595B2
(en)
*
|
2011-04-29 |
2016-02-09 |
Bae Systems Information And Electronic Systems Integration Inc. |
Optical dome bezel
|
|
LT2723379T
(lt)
*
|
2011-06-23 |
2018-10-25 |
Biogen International Neuroscience Gmbh |
Anti-alfa sinukleiną rišančios molekulės
|
|
US20130156766A1
(en)
*
|
2011-11-15 |
2013-06-20 |
Allergan, Inc. |
Treatment of dry age related macular degeneration
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
CA2966905A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
CN105821029A
(zh)
*
|
2015-01-04 |
2016-08-03 |
彭霞 |
异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
|
|
CN113862300A
(zh)
*
|
2015-10-29 |
2021-12-31 |
豪夫迈·罗氏有限公司 |
具有共同轻链的转基因兔
|
|
CN106928355B
(zh)
*
|
2015-12-30 |
2020-09-29 |
广西医科大学 |
一种CD105纳米抗体Nb184
|
|
CN106928359B
(zh)
*
|
2015-12-30 |
2020-10-13 |
广西医科大学 |
一种CD105纳米抗体Nb59
|
|
US10729771B2
(en)
|
2016-02-10 |
2020-08-04 |
Rutgers, The State University Of New Jersey |
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
|
|
CN117205321A
(zh)
*
|
2016-06-14 |
2023-12-12 |
西达-赛奈医疗中心 |
通过内皮糖蛋白拮抗作用使肿瘤对疗法敏感
|
|
SI3672631T1
(sl)
|
2017-08-22 |
2023-06-30 |
Biogen Ma Inc. |
Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
|
|
CN108912212B
(zh)
*
|
2018-06-28 |
2019-08-30 |
中山大学附属口腔医院 |
一种与cd105特异性结合的多肽及其应用
|
|
WO2020106461A2
(en)
*
|
2018-11-08 |
2020-05-28 |
Celldex Therapeutics, Inc. |
Anti-mertk antibodies and methods of use thereof
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
WO2021206636A1
(en)
*
|
2020-04-07 |
2021-10-14 |
Agency For Science, Technology And Research |
ANTIGEN-BINDING PROTEIN TO SARS-CoV-2
|
|
CN112426526B
(zh)
*
|
2021-01-25 |
2021-04-06 |
北京达熙生物科技有限公司 |
一种nk细胞的制备方法及其在治疗癌症中的应用
|
|
CN112876538B
(zh)
*
|
2021-02-04 |
2022-09-30 |
福建医科大学 |
靶向新生血管标记物cd105的多肽及其应用
|
|
WO2022187710A1
(en)
*
|
2021-03-05 |
2022-09-09 |
Atreca, Inc. |
Epha2 antibodies
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4469479A2
(en)
*
|
2022-01-24 |
2024-12-04 |
Genovac Antibody Discovery LLC |
Anti-alk1 antibodies and methods of using the same
|
|
EP4572772A1
(en)
|
2022-08-17 |
2025-06-25 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
EP4627096A1
(en)
|
2022-12-02 |
2025-10-08 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025045032A1
(zh)
*
|
2023-08-29 |
2025-03-06 |
应世生物科技(南京)有限公司 |
一种靶向cd105的抗体或其抗原结合片段及其应用
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
TWI882851B
(zh)
*
|
2024-06-27 |
2025-05-01 |
蔡政育 |
基於專利技術元素整合之專利分析系統及其方法
|